The Russian Direct Investment Fund (RDIF) and ADIENNE Pharma & Biotech signed an agreement on the production of the Sputnik V vaccine in Italy.
This was reported in a press release from the Italian-Russian Chamber of Commerce, which is at the disposal of RIA Novosti.
As specified, previously the Italian company Adienne Srl. (part of the ADIENNE Pharma & Biotech holding) put forward a proposal to sign a strategic agreement for the local production of a Russian vaccine.
“For the first time in Europe, an agreement was signed between the Russian State Direct Investment Fund and ADIENNE Pharma & Biotech on the production of the Sputnik V vaccine in Italy,” the Italian-Russian Chamber of Commerce said.
Local production, according to the chamber, should start in July. It is expected that this will create new jobs and fully control the production process of the drug.
On March 7, it became known that RDIF intends to cooperate with the Swiss company ADIENNE Pharma & Biotech to produce the Sputnik V vaccine in Italy.